This is a preview and has not been published.

Effect of omega-3 fatty acıd added to parenteral nutrıtıon on ınflammatory process ın preterm ınfants

Authors

  • GUZİN TUMER a:1:{s:5:"en_US";s:25:"ONDOKUZMAYIS UNİVERSİTY";}
  • Ayhan Dağ Lokman Hekim University Dietetic and Nutrition
  • Seyit Mercanlıgil Uluslararası Kıbrıs University Faculty of Health Sciences Nutrition and Dietetics Department.
  • Canan Aygun Seren Ondokuzmayıs University Neonatology

Keywords:

Keywords: Omega-3 fattyacid, inflammation markers, prematüre, parenteral nutrition

Abstract

Background:This study aimed to investigate the effect of omega-3 fatty acid addition to Total Parenteral Nutrition (TPN) on the inflammatory process and clinical outcomes.

Methods: The study included 51 infants who were in the Neonatal Intensive Care Unit (NICU) and fed by TPN for minimum 10 days, with a gestational age of ≤32 weeks and a birth weight of ≤2500g. The preterm infants fed by TPN with 80% omega-9 and 20% omega-6 fatty acids were determined as Group 1(n:26) and by TPN with added omega-3 fatty acid (0.7g/day) as Group 2(n:25). This retrospective study retrieved demographic characteristics, anthropometric measurements, nutrition therapy details, comorbidity development, inflammatory markers, and laboratory and clinical results from patient files. Those who received exchange transfusions and who received TPN for less than 10 days were excluded from the study.

Results: Comorbidity developed in 35% of Group 1 and 28% of Group 2, with no difference between the groups (p < 0.05). There was no difference in gestational week at birth, birth weight, duration of mechanical ventilation (MV), duration of oxygen support, and maternal age between the two groups (p < 0.05). There was no difference in the carbohydrate (CH), protein and lipid levels, and glucose infusion rate (GIH) between the two groups (p <0.05). In Group 2, the daily amount of omega-3 fatty acid was increased by 0.7 ± 0.1 g/day, accounting for 6,6 ± 0.03% of the total energy. There was a significant decrease in the blood levels of Aspartate Aminotransferase (AST) and Total Bilirubin (T.Bil) on day 10 ​​in Group 2 (p < 0.05). Procalcitonin (PCT) significantly decreased on days 1, 4, 7, and 10 in both groups (p < 0.05). The difference in C-Reactive Protein (CRP) on days 4 and 10, and PCT and Neutrophil-to-Lymphocyte Ratio (NLR) on days 1, 4, 7,10 was insignificant, with lower values in Group 2.

Conclusion: The present study established a low level of positive changes in inflammatory findings and a decrease in liver function test results with the addition of fish oil to TPN. The different fatty acid contents of ILEs, the optimum ratio between the fatty acids, and the amount and duration of use affect the clinical outcomes. Further studies are needed to determine a safe, adequate dose and appropriate fatty acid profile.

 

Downloads

Download data is not yet available.

##submission.citations##

REFERENCES

Morgan C, McGowan P, Herwitker S, Hart A, Turner M. Postnatal head growth in preterm infants: a randomized controlled parenteral nutrition study. Pediatr. 2014;133:120-8.

Alexandre L, Marie-PB, Yvette B, Sophie C. Safety of parenteral nutrition in newborns: Results from a nation wide prospective cohort study. ClinNut. 2018;37:624-629.

Victoria AP, Alicia JS, Katherine JL, Peter A, Thomson DK, Doyle LW et al. Nutrition, Growth, Brain Volume, and Neurodevelopment in Very Preterm Children. J Pediatr. 2019;1-6.

Paola R, Nadia L, Camilla M,Fabio M. New Insights in Preterm Nutrition. Nutr. 2020;12:1857-1861.

Lapillonne A, Groh-Wargo S, Gonzalez CH, Uauy R. Lipid needs of preterm infants: updated recommendations. J Pediatr. 2013;162:37–47.

Alexandre L, Sissel J.M. Long-Chain Polyunsaturated Fatty Acids and Clinical Outcomes of Preterm Infants. Ann Nutr Metab. 2016;69(1):36–44.

Lapillonne A, Fidler NM, Goulet O, Chris H.P. Jennifer W et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids. Clin Nutr. 2018;37:2324-2336.

Tian H, Lu Y, Shah SP, Hong, S. Autacoid 14S, 21R-dihydroxy-docosahexaenoic acid counter acts diabetic impairment of macrophage prohealing functions. Am J Pathol. 2011;179:1780–1791.

Stanislaw K. Omega-3 Fatty Acids in Modern Parenteral Nutrition: A Review of the Current Evidence. J Clin Med. 2016;5:34-50.

M Hacımustafaoğlu. Procalcitonin as aacute phase reactant. J Pediatr Inf. 2017;11(4): 196-19.

K Westerdijk, K S. Simons, M Zegers, P C.Wever, P Pickkers, Cornelis PC. The value of the neutrophil-lymphocyte count ratio in the diagnosis of sepsis in patients admitted to the Intensive Care Unit: Are rospective cohort study. PLOS ONE | https://doi.org/10.1371/journal.pone.0212861 February 27.2019;1-13.

FC Eraldemir. Neutrophil/Lymphocyte Ratio Instead of Procalcitonin: Is it an Option? Türk klinik biyokimya derg. 2018;16(1):11-16.

Guthrei G, Premkumar M, Burrin DG. Emerging clinical benefits of new-generation fat emulsions in preterm neonates. Nutr clin pract. 2017;32(33):326-36.

Ünal S, Ulubaş D I, Arifoğlu İ, Erol S, Demirel N, Baş AY. Evaluation of Liver Function Tests in Preterm Infants Receiving Parenteral Lipid Emulsions Based on Fish Oil or Olive Oil. Turkish J Pediatr Dis. 2018;2:124-130.

H Yildizdas, B Poyraz, G Atlı, Y Sertdemir, K Mert, Özlü F. et al. Effects of two different lipid emulsions on antioxidant status, lipid peroxidation and parenteral nutrition- related cholestasis in premature babies, a randomized-controlled study. Pediatr and Neo. 2019; 60:359-367.

D’Ascenzo R, Savini S, Biagetti C, Bellagamba MP, Marchionni P, Pompilio A, et al. Higher docosahexaenoic acid, lower arachidonic acid and reduced lipid tolerance with high doses of a lipid emulsion containing 15% fish oil: A randomized clinical trial. ClinNutr. 2014;33:1002-9.

Savini S, D’Ascenzo R, Biagetti C, Serpentini G, Pompilio AB, Cogo PE et al. The effect of 5 intravenous lipid emulsions on plasma phytosterols in preterm infants receiving parenteral nutrition: a randomized clinical trial. Am J Clin Nutr. 2013;98(2):312–318.

Zhao Y, Wu Y, Pei J, Chen Z, Wang Q, Xiang B. Safety and efficacy of parenteral fish oil – containing lipid emulsions in prematüre neonates. JPGN 2015;60:708-716.

Yakah W, Cortijo DR, Singh P, Browm J, Stoll B, Kulkarni M et al. Parenteral fish-oil contaning lipid emülsions limit initial lipopolysaccharide-ınduced host immune responses in preterm pigs. Nutr. 2021;13: 205-223.

Housny M, Nahas R, Sheeren A, Elshafei SA, Kahaled H. Impact of oral omega-3 fatty acids supplementation in early sepsis on clinical outcome and immunomodulation. The Eygptian J Crit care med. 2013;1:119-126.

Klek S, Wierzbicka DM, Scislo L, Walewska E, Pietka M, Sczepanek K. High Dose Intravenous Fish Oil Reduces Inflammation—A Retrospective Tale from Two Centers. Nutrients. 2020;12(9):2865-2873

Lapillonne A, Moltu S J. Long-chain polyunsaturated fatty acids and clinical outcomes of preterm infants. Ann Nutr Metab. 2016;69(1):36-44.

Dasilva G, Pazos M, García-Egido E, Gallardo JM, Rodríguez I, Cela R, et al. Healthy effect of different proportions of marine ω-3 PUFAs EPA and DHA supplementation in wistarrats: Lipidomicbio markers of oxidative stress and inflammation. J Nutr Biochem. 2015;26(11):1385-92.

Vanek WV, Seidner DL, Bistrain B, Gura K, Allen P, Collier S. et al. ASPEN position paper: clinial role for alternative intravenous fat emulsions. Nutr clin pract. 2012;27(2):150-192.

Calkins K L, Robinson D T. Intravenous lipid emulsions in the NICU. http://neoreviews.aappublications.org/ at Bibliotheque Univ Paris. 2020;(2)21:109-119.

Edward RR, Innes JK, Marino VL, Calder FC. Influence different intravenous lipid emulsions on growth, development and laboratory and clinical outcomes in hospitalized pediatric patients: A systematic review. Clinical nutr. 2018;37:765-783

Aydın İ, Ağıllı M, Aydın F N, Kurt Y G, Çaycı T, Taş A. et al. The reference ranges of neutrophil-lymphocyte ratio in different age groups Gülhane tıp derg. 2015;57:414-418.

Serhan, C.N.; Chiang, N.; Dyke, T.E. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008; 8, 349–361.

Gabbs, M, Leng, S, Devassy, J.G, Monirujjaman, M, Aukema, H.M. Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. Adv. Nutr. 2015; 6, 513–540.

Harauma A, Yasuda H, Hatanaka, E, Nakamura M.T, Salem, NJ, Moriguchi, T. The essentiality of arachidonic acid in addition to docosahexaenoic acid for brain growth and function. Prostaglandins Leukot. Essent. Fatty Acids. 2017; 116, 9–18.

Kapoor V, Soll R. Lipid emulsions for parenterally fed preterm infants. Cochrane database of Syst Rev. 2019;(4)6:6.

Deshpande GC, FRACP MS, Cai W. Use of Lipids in Neonates Requiring Parenteral Nutrition. ASPEN. 2020;44(1):45-54.

Guthrie G, Burrin D. İmpact of parenteral lipid emulsion compenents on cholestatic liver disease in neonates. Nutr. 2021;13(2): 508-527.

Section

Original article Clinical Research